arrow
M

Mai Onishi

dana-farber cancer institute
H指数:7
被引数:155

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians

更正:MIRAY1的初始活动与展望:一个由青年主导、社会认可的培养未来乳腺癌医师的倡议

2026-09-060
PRE
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors

M1C是耐药KRAS抑制剂的非小细胞肺癌KRAS G12C突变肿瘤的可成药靶点

2026-08-050
OA
Clinical impact of rapid test for macrolide-resistance gene mutation among cases with Mycoplasma pneumoniae in Japan

日本肺炎支原体病例中,快速检测大环内酯耐药基因突变的临床影响

2025-08-130
OAAI
Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B)

激素受体阳性,HER2-negative乳腺癌患者早期复发的危险因素: 日本的一项回顾性队列研究 (WJOG15721B)

2025-04-010
OAAI
Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients
2022-02-150
PRE
Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)
2021-01-029
OAAI